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Conclusions. We hypothesize that the increased number ofThe Duffy antigen receptor for chemokines is up-regulated
DARC-positive venules in areas of interstitial injury and theduring acute renal transplant rejection and crescentic glomeru-
colocalization with CCR5-positive infiltrating leukocytes maylonephritis.
indicate a role for endothelial DARC expression during leuko-Background. Recruitment of leukocytes during immune re-
cyte adhesion and interstitial infiltration.sponses requires the coordinate expression of adhesion mole-
cules in concert with chemokines and their receptors. The
Duffy antigen receptor for chemokines (DARC) binds multiple
chemokines and is expressed on postcapillary venules in the
During acute transplant rejection and crescentic glo-normal kidney. The chemokine receptor CCR5, which shares
merulonephritis (cGN), a cell-mediated immune responsethe ligand regulated upon activation, normal T-cell expressed
and secreted (RANTES) with DARC, is expressed by infiltrat- leads to an influx of mononuclear leukocytes, mainly T
ing T cells in the renal interstitium. As DARC might be in- cells and macrophages, into different compartments of
volved in the attraction of CCR5-positive cells, we studied the the kidney [1–3]. This requires the concerted action ofdistribution of DARC and CCR5 in two forms of cell-mediated
chemokines and adhesion molecules on infiltrating cellsrenal injury: renal allograft rejection and crescentic glomerulo-
and the local endothelium [4]. Chemokines are smallnephritis (cGN).
Methods. A total of 87 renal specimens, including 12 pre- chemotactic proteins that are presently divided into four
transplant biopsies, 47 transplant biopsies (Banff 1, N 5 10; subgroups (CC, CXC, C, and CX3C chemokines) ac-Banff 2, N 5 19; and various other lesions N 5 18), and 28 cording to their primary structure [reviewed in 5–7]. Thebiopsies from patients with cGN, was analyzed. Immunohisto-
interaction of chemokines with their respective receptorschemistry for CCR5 and DARC was performed on serial sec-
is essential for the local accumulation of specific inflam-tions of formalin-fixed and paraffin-embedded tissue.
Results. Compared with pretransplant biopsies, the mean matory cells. The Duffy blood group antigen was identi-
number of DARC-positive interstitial venules was significantly fied as a chemokine receptor and was therefore renamed
increased during both transplant rejection and cGN. This was Duffy antigen receptor for chemokines (DARC) [8].accompanied by an infiltration of CCR5-positive leukocytes.
DARC can bind several chemokines of different sub-During transplant rejection, the number and distribution of
groups, like regulated upon activation, normal T-cell ex-CCR5-positive cells correlated with DARC-positive venules.
Infiltrating CCR5-positive leukocytes were found mainly in the pressed and secreted (RANTES), monocyte chemoat-
interstitium, often clustering around Bowman’s capsules in tractant protein-1 (MCP-1), and interleukin-8 (IL-8)
biopsies from cGN. The number of glomerular CCR5 positive [8–10]. In addition to red blood cells, DARC is expressedcells is low, but they are common in a subset of crescents.
on the endothelium of postcapillary venules of lymph
nodes, spleen, and the kidney [11, 12]. The DARC ex-
1 See Editorial by Lappin and Brady, p. 1816 pression on endothelium is present even in individuals
who are Duffy negative on erythrocytes [13]. The func-
Key words: immune response, cell-mediated renal injury, allograft re-
tion of DARC is still unknown, and binding of chemo-jection, venules, endothelial DARC expression, leukocyte adhesion,
kidney rejection. kines does not lead to the classic G-protein–coupled
signal transduction of chemokine receptors. DarbonneReceived for publication January 28, 2000
et al proposed a function of DARC on red blood cellsand in revised form April 21, 2000
Accepted for publication May 1, 2000 as a systemic “sink” for chemokines, but the role of
DARC on endothelial cells remains to be defined [9, 12].Ó 2000 by the International Society of Nephrology
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A recent study demonstrated an up-regulation of DARC CCR5 and the applicability on paraffin-embedded mate-
on glomerular endothelium, collecting duct epithelium, rial have previously been described in detail [32]. CD3-
and interstitial cells in children with HIV-associated re- positive T cells (Dako, Hamburg, Germany) and CD68-
nal diseases [14]. positive macrophages (Dako) were evaluated in patients
The chemokines macrophage inflammatory protein-1a with cGN when appropriate biopsy material was avail-
(MIP-1a), MIP-1b, and RANTES are expressed in the able. A monoclonal rat antibody (MECA-79, ATCC num-
kidney during transplant rejection and cGN. Inhibition ber HB-9479) against high endothelial venules in lymphoid
of RANTES in experimental transplant rejection and tissues was used on human tonsils and renal transplant
cGN shows beneficial effects [15–28]. The mentioned biopsies [34].
chemokines bind to the chemokine receptor 5 (CCR5) Immunohistochemistry was performed on 2 mm thick
and are able to induce transendothelial chemotaxis of serial sections of formalin-fixed, paraffin-embedded ma-
T-cell subsets in vitro [29, 30]. T cells, macrophages, natu- terial as previously described [32]. In brief, slides were
ral killer cells, and dendritic cells express CCR5 [31]. We deparaffinized in xylene and rehydrated in graded etha-
recently demonstrated that a major part of the interstitial nols. Endogenous peroxidase was blocked by 3% H2O2infiltrating cells in various forms of renal disease, includ- in methanol for 15 minutes. Antigen retrieval was per-
ing transplant rejection, are CCR5-positive T cells [32].
formed by microwave treatment in a citrate-based buffer.
In the present study, we examined the distribution of
First antibody was applied for one hour. For signal ampli-CCR5-positive infiltrating leukocytes in relationship to
fication and color development, a commercial biotin-DARC-positive venules. In areas of renal injury, we de-
streptavidin kit was used according to the instruction ofscribe an up-regulation of DARC on the endothelium
the manufacturer (Super Sensitive Ready to Use Kit; Bio-and a colocalization with CCR5-positive leukocyte infil-
genex, San Ramon, CA, USA). After counterstainingtrates. We propose that DARC expressed on endothelial
with hemalaun, slides were embedded in Aquatex (Merck,cells might act as a presenter of chemokines, and thus
Darmstadt, Germany).contribute to the local adhesion and infiltration of CCR5-
For the quantitation of the immunohistochemistry, pos-positive cells at the site of renal injury.
itive cells or positive vessels were counted in 10 high-
power fields (3400) for each biopsy by one observer with-
METHODS out knowledge of the diagnosis of the transplant biopsies.
We studied a total of 87 renal biopsies, including 12 CCR5-positive cells were separately counted in the inter-
pretransplant biopsies, 47 transplant biopsies, and 28 stitium and in glomeruli. Mean cell counts were compared
biopsies from patients with cGN. by Wilcoxon test. Correlations were evaluated with the
The transplant biopsies were from patients with acute Spearman-Rho correlation coefficient, and P , 0.05 was
interstitial transplant rejection (Banff 1, N 5 10) and considered statistically significant. Bars give the SEM.
acute vascular rejection (Banff 2, N 5 19) according
to the Banff classification [33]. To evaluate the course
RESULTSof CCR5 and DARC expression, we studied repeated
biopsies. In addition to acute transplant rejections, this DARC expression on two different types of venules in
group included 18 biopsies with various other lesions the tonsil, including the sites of leukocyte recirculation
like no rejection, borderline lesions, thrombotic mi-
The monoclonal anti-DARC antibody (2C3) with spe-
croangiopathy, and chronic transplant rejection (as well
cificity for the Fy6 antigen was used on human tonsilsas cases in which the material was insufficient for a defin-
to optimize the immunostaining conditions. To identifyitive diagnosis). The cGN population included cytoplas-
the distribution of DARC-positive venules, we used themic IF antineutrophil cytoplasmic antibodies (c-ANCA)
monoclonal rat antibody MECA-79. This antibody binds(N 5 8) and perinuclear (p-ANCA) positive (N 5 4),
to addressins on high endothelial venules of lymphcrescentic lupus nephritis (N 5 1), Goodpasture’s syn-
nodes, which serve as adhesion molecules involved indrome (N 5 1), and unclassified patients (N 5 3).
lymphocyte homing [35, 36]. DARC is expressed on twoThe monoclonal anti-DARC antibody of Fy6 specific-
types of venules in human tonsils, as shown in Figure 1.ity (clone 2C3) was raised in Balb/C mice by immuniza-
The first and most common type of DARC-positivetion with Chinese hamster ovary (CHO) cells expressing
endothelium has the same distribution and morphologythe Duffy glycoprotein. The monoclonal antibody 2C3
as high endothelium venules stained with MECA-79agglutinated DARC-positive [Fy(a1) and Fy(b1)] but
(Fig. 1B, C). The second are venules with a flat endothe-not DARC-negative [Fy(a2b2)] red blood cells. The
lium, which display no reactivity with MECA-79 (dataspecificity was shown by flow cytometry and immuno-
not shown). Omitting the first antibody completely abol-blotting [abstract; Blanchard et al, Vox Sang 74(Suppl 1):
71, 1998]. The monoclonal antibody MC5 against human ished the signal (Fig. 1A).
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Fig. 1. Immunohistochemistry for the Duffy antigen receptor for chemokines (DARC) and rat monoclonal antibody (MECA-79) on human tonsils
and for DARC on pretransplant control biopsies. (A) Negative control (first antibody replaced by diluent, original 3400). (B) Parallel section
stained with a monoclonal antibody against DARC (2C3, original 3400). Note the two different types of venules stained for DARC with high
endothelium (arrow) on the left and flat endothelium on the right (arrowhead). (C ) High endothelial venules stained with MECA-79 (arrow,
original 3200). In pretransplant renal biopsies (D and E ), only a few DARC-positive small postcapillary venules are seen (arrow, D, original
3100) and a single DARC-positive venule in the lower half of E (arrowhead, original 3200).
The number of DARC-positive venules in normal The up-regulation of DARC was not specific for
allograft rejection but was a feature of cGNrenal tissue was low
In contrast to the recent description of the expression In biopsies with cGN, the distribution of DARC at sites
of interstitial infiltration closely resembled the stainingof MECA-79 in heart transplantation, we did not find any
MECA-79 reactivity in over 20 renal specimens, ranging pattern in biopsies undergoing transplant rejection (Figs. 3
and 5C, D). Attachment of leukocytes to DARC-positivefrom normal renal tissue to severe transplant rejection
(data not shown) [37]. In contrast, DARC staining was endothelia of interstitial venules was a common feature
(Fig. 5C). In contrast to the prominent increment ofpresent on some peritubular venules in pretransplant biop-
sies (Fig. 1D, E). Vessels that stained positive for DARC DARC-positive interstitial venules, we could not detect
DARC staining on glomerular endothelium. Liu et alwere on average larger in diameter compared with the
size of the vessel wall than the majority of interstitial described DARC-positive cells outside the endothelium
in interstitial infiltrates [14]. We found only a very smallcapillaries. Although they did not stain with MECA-79,
endothelial cells were larger and higher, similar to those number of DARC-positive cells outside the endothe-
lium. These cells did not show a distinct pattern andseen in high endothelial venules (as compared with other
peritubular vessels). Taking these morphological findings could not be further characterized.
together, we assumed that these vessels represent post-
The tubulointerstitium was the main site ofcapillary venules. For simplicity, they are referred to as
CCR5-positive leukocyte infiltrationvenules for the remainder of this article. No DARC
expression was found on the endothelium of glomerular The number of CCR5-positive infiltrating leukocytes
in pretransplant biopsies was low (Fig. 3). The up-regula-capillaries or on endothelium of arteries. In pretrans-
plant biopsies, the mean number of DARC positive ven- tion of DARC was accompanied by an infiltration with
CCR5-positive cells during acute transplant rejectionules was low (0.3 positive vessels per high-power field).
The distribution of DARC in the normal kidney is consis- (Fig. 3). A major part of the leukocytes infiltrating the
renal allograft interstitium expressed CCR5 during rejec-tent with previous publications [11, 14].
tion episodes (Fig. 4B, C, E), and CCR5-positive leuko-
The number of DARC-positive venules increased cytes were present at all sites of allograft rejection, that
during transplant rejection is, tubules, endothelia, and occasionally glomeruli (Fig.
4C–E). A single biopsy with acute vascular transplantIn allograft biopsies from patients with acute rejection,
the mean number of DARC-positive venules is signifi- rejection and acute transplant glomerulopathy showed a
high number of CCR5-positive cells within the glomeruli.cantly higher than in pretransplant biopsies (Figs. 2B, D;
3; and 4A). DARC-positive venules were especially In cGN, as in other glomerular diseases, the main site
of CCR5-positive cell infiltration was the tubulointerstit-prominent at sites of strong interstitial leukocyte infil-
tration (Fig. 2A). There was no difference regarding the ium (Fig. 5B, E) [32]. A prominent clustering of CCR5-
positive cells was apparent in the interstitium surroundingexpression pattern and number of DARC-positive ven-
ules between patients with interstitial and vascular rejec- the glomeruli in early cell-rich stages of cGN resembling
cellular cuffing of glomeruli (Fig. 5E). Forty percent of cel-tion (Fig. 3). Even in vascular rejection, no DARC ex-
pression was detected on endothelium of glomerular lular crescents contained CCR5-positive cells (Fig. 5A, B),
while CCR5-positive cells were rarely found in intact glo-capillaries and arteries. Attachment of leukocytes to
DARC-positive endothelia and transmigration was ap- merular capillary loops, consistent with our previous obser-
vation in other forms of glomerulonephritis [32].parent in transplant rejection, as illustrated in Figure 4F.
c
Fig. 2. Immunohistochemistry of renal transplant biopsies from patients with acute vascular rejection stained with a monoclonal anti-DARC
antibody (A, original 3100; B, original 3200; and D, original 3400) or with a monoclonal anti-CCR5 antibody (C, original 3400). Note the
prominent DARC expression on venules located in areas of interstitial infiltration in A (arrow). (B) Note the high number of DARC-positive
venules (arrowhead, compare Figure 1D and E). (C) Note the number of CCR5-positive cells surrounding the DARC-positive venules on a parallel
section of D.
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Fig. 3. Mean numbers of DARC-positive ven-
ules (A) and chemokine receptor 5 (CCR5)-
positive cells (B) per high-power field in pre-
transplant biopsies, in biopsies with acute in-
terstitial rejection (Banff 1, P, 0.01 vs. pretrans-
plant), in biopsies with acute vascular rejection
(Banff 2, P , 0.01 vs. pretransplant), and in
biopsies with cGN (P , 0.01 vs. pretransplant).
Morphologically, two types of CCR5-positive cells expressed CCR5, and these cells could be located in and
around DARC-positive venules (Figs. 2C and 4F, G).were distinguishably clustered around and within cellular
crescents. The majority of the cells consisted of small, Besides the colocalization in areas of interstitial infiltra-
tion of CCR5-positive leukocytes and DARC-positiveround cells with prominent expression of CCR5 similar
to most of the CCR5-positive cells within the interstitium venules, the mean number of DARC-positive venules
correlated significantly with the mean number of CCR5-(Fig. 5A). These cells were identified as CD3-positive
lymphocytes on consecutive sections. The other cell type positive cells (R2 5 0.35, Spearman-Rho correlation coef-
ficient, 0.659, P , 0.01).represented by larger cells exhibited a slightly weaker
CCR5 staining (Fig. 5B). Morphologically and by immu- To evaluate the time course of DARC expression and
CCR5-positive cells, we obtained data from patients withnohistochemistry on serial sections, these cells could be
identified as CD68-positive macrophages. Interestingly, repeated biopsies. Two patients with pretransplant biop-
sies and later acute vascular rejection showed a strongalthough we found CD68-positive cells within glomerular
tufts, these cells did not express CCR5. In concordance increase in both the number of interstitial DARC-posi-
tive venules and CCR5-positive cells. Figure 6 illustrateswith our previous data, we could not demonstrate CCR5
expression on intrinsic renal cells [32]. the course of the mean number of DARC-positive ven-
ules and CCR5-positive cells in a patient with seven
In transplant rejection, CCR5-positive cells and biopsies of the same transplant. The numbers were low
DARC-positive venules show a morphological in two biopsies without signs of acute rejection. The
and numerical correlation first episode of interstitial rejection led to the strongest
increment of DARC expression and CCR5-positive cells.As described previously in this article, DARC-positive
venules were mainly localized in areas of interstitial leu- One later episode of vascular rejection again led to an-
other increase of both DARC-positive venules andkocyte infiltration. A main part of these infiltrating cells
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Fig. 4. Immunohistochemistry of renal transplant biopsies from patients with acute interstitial rejection (Banff 1, in A, B, and C ) or with acute
vascular rejection (Banff 2, in D, E, F, and G ) stained with a monoclonal anti-DARC antibody (A, original 3200; F, original 31000) and with a
monoclonal anti-CCR5 antibody (B, original 3200; C, D, and E, original 3400; G, original 31000). Note the high number of DARC-positive
interstitial venules in A, but the absence of DARC on glomerular endothelium. (C and D) The infiltration of CCR5-positive cells in tubulitis (C)
and acute allograft glomerulopathy (D). (E) The massive infiltration of the interstitium by CCR5-positive cells. (F and G) Parallel sections and
colocalized CCR5-positive cells with a DARC-positive capillary. One leukocyte is just transmigrating the endothelium in F (arrow). Most of the
cells within the DARC-positive vessel are CCR5 positive (arrowhead in G; G, original 31000 is a higher magnification of E). Reproduction of
this figure in color was sponsored by Fresenius Medical Care Deutschland GmbH.
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Fig. 5. Immunohistochemistry of renal biopsies from patients with cGN stained with a monoclonal antibody against CCR5 (MC5, A, B, and E,
original 3400) and with a monoclonal antibody against DARC (2C3, C and D, 3400). Note the two different types of CCR5-positive cells in
crescents: the small cells with strong CCR5 staining in A (arrow) and the large cell type with a weak membrane staining in B (arrowhead). A
leukocyte sticks to the DARC-positive endothelium in C (arrow). DARC-positive venules are localized at sites of infiltration (arrowhead) in D.
(E) Note the prominent clustering of CCR5-positive cells around Bowman’s capsules. Reproduction of this figure in color was sponsored by
Fresenius Medical Care Deutschland GmbH.
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Fig. 6. The mean number of DARC-positive
venules (right) and CCR5-positive cells (left)
in seven biopsies of the same transplant. The
diagnoses are given on the x axis (chr. tx: signs
of chronic transplant rejection; borderline,
borderline lesions). Note the parallel course of
(r) DARC-positive venules and ( ) CCR5-
positive infiltrating cells.
CCR5-positive cells. This case illustrates the up-regula- CCR5-positive cells were rare within the glomerular tuft
in either transplant rejection or cGN.tion during an acute episode of transplant rejection and
Expression of DARC in the normal kidney has beena decrease of the number of DARC-positive venules in
described by immunohistochemistry and in situ hybrid-a later biopsy without acute rejection. Furthermore, it
ization with somewhat conflicting results. Consistent withshows a parallel course of DARC-positive venules and
our data, DARC expression was found on a subset ofCCR5-positive cell infiltration.
endothelial cells lining postcapillary venules and peritu-
bular capillaries [11, 14, 38]. Chaudhuri et al demon-
DISCUSSION strated DARC expression on endothelium of glomeruli
The major findings of this study can be summarized and principal cells of collecting ducts, in addition to peri-
as follows: (1) DARC is expressed on the endothelium tubular capillaries in a detailed morphological study [38],
of a low number of postcapillary venules in the normal whereas other groups found no DARC expression on
human kidney. In contrast to a high expression in the tubular epithelium or glomerular capillaries in the nor-
endothelium of tonsils, DARC-positive endothelial cells mal kidney [11, 14]. In concordance with Liu and Hadley,
in the kidney do not express the addressins labeled by we did not detect DARC expression on glomerular endo-
MECA-79. (2) During cell-mediated injury of transplant thelial cells in control biopsies. The differences in DARC
rejection or cGN, the expression of DARC increases expression on tubular epithelia and glomerular endothe-
markedly on the endothelium of venules, but not on lium between these studies may be due to different un-
glomerular or arterial endothelium. In contrast to the derlying diseases, different sensitivities and specificities
description in heart transplants, we found no MECA-79 of the applied antibodies, for example, monoclonal ver-
reactivity on renal endothelia during transplant rejection sus polyclonal, or to differences in tissue preparations,
and in normal specimens. (3) DARC-positive peritubu- for example, frozen versus paraffin-embedded material.
lar venules are located in areas of interstitial infiltrates At present, clear evidence exists for DARC expression
consisting mainly of CCR5-positive cells. During trans- on endothelia of a restricted type of venules in the normal
plant rejection, this results in a positive correlation be- kidney, and we describe a markedly increased DARC
tween the mean number of DARC-positive venules and expression on endothelia of peritubular venules during
CCR5-positive cells. In individual cases, a parallel rise transplant rejection and cGN.
and fall of DARC-positive venules and CCR5-positive The monoclonal antibody MECA-79 binds to several
interstitial infiltrates during rejection episodes could be L-selectin ligands, which are involved in lymphocyte
documented. (4) Intrinsic renal cells do not express homing to lymph nodes [39]. A differential expression
CCR5 in normal kidneys during transplant rejection and of DARC and colocalization with MECA-79–positive
cGN. CCR5-positive leukocytes account for a major part high endothelial venules has recently been described
of the interstitial infiltrates during transplant rejection [40]. The absence of MECA-79 staining during renal
and cGN. Crescents contain two types of CCR5-positive allograft rejection is in contrast with an up-regulation of
cells, which morphologically and by immunohistochem- MECA-79 reactivity during heart transplant rejection,
and points toward differences in the counter-receptorsistry represent T cells and macrophages. In contrast,
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or the decoration of counter-receptors involved in the dance with the expression of the CCR5 ligands MIP-1a
and MIP-1b [28]. We could distinguish two subsets ofinfiltration of renal allografts [37].
The up-regulation of DARC on endothelial cells at CCR5-positive cells, most likely representing macro-
phages and T cells in the crescents. The presence ofsites of inflammation leads to the question of DARC
function. In lymphoid organs such as tonsils, DARC is CCR5-positive macrophages in crescents and their ab-
sence within the glomerular tuft of cGN or noncrescenticconstitutively expressed on high endothelial venules, the
site of T-cell transmigration, and homing. In the kidney, lupus nephritis imply differences in chemokine receptor
expression between certain macrophage populations, asDARC is expressed at sites where the extravasation of
leukocytes into the interstitium is thought to take place. CCR5-negative macrophages are present in the glomeru-
lar tuft in these biopsies. Of interest is the marked peri-The cascade of interactions between adhesion molecules,
chemokines, and chemokine receptors during adhesion glomerular infiltrate with CCR5-positive cells. These
might be involved in the rupture of Bowman’s capsule,and transmigration of leukocytes is most effective in
vascular beds with low shear stress. In the kidney, these leading to the invasion of interstitial cells, that is, T cells
are postglomerular capillaries and venules, the site of and fibroblasts, and result in irreversible fibrosis of the
DARC up-regulation. In fact, adherent and transmigrat- glomerulus, as described in animal models [46].
ing leukocytes could be observed on DARC-positive Although crescent formation is a feature of severe
endothelia of venules during transplant rejection and glomerular injury, we did not detect DARC expression
cGN (Figs. 4F and 5C). The parallel course of changes on endothelial cells of glomerular capillaries. Thus, the
in DARC-positive venules and CCR5-positive leukocyte positive correlation of DARC-positive endothelia with
infiltrates observed in serial biopsies from one transplant CCR5-positive infiltrates also holds true in the negative
strongly suggests the participation of DARC and CCR5 sense; that is, DARC-negative endothelia rarely show
in a common process during transplant rejection (Fig. 6). CCR5-positive infiltrates.
As a hypothesis, we propose that chemokines may be In summary, our results show a marked up-regulation
presented by DARC on the surface of activated endothe- of DARC on postglomerular endothelia in areas of inter-
lia in postglomerular venules and thus participate in the stitial and periglomerular infiltrates in both transplant
local adhesion and transmigration of CCR5-positive cells. rejection and cGN. These areas are also those with a
Besides our morphological data, experimental studies sup- CCR5-positive leukocyte infiltrate. The concordance of
port this hypothesis. Middleton et al demonstrated the these phenomena suggest that DARC on endothelia and
localization of the DARC ligand IL-8, but not MIP-1a on chemokine receptors on leukocytes, together with their
the luminal surface of endothelial cells after intradermal ligands such as RANTES, may work hand in hand during
injection [41]. An alternative hypothesis of DARC acting leukocyte adhesion and transmigration in cell-mediated
as a “sink” for chemokines and perhaps functioning as renal injury.
an anti-inflammatory molecule cannot be ruled out by
our morphological data. However, the recent description
NOTE ADDED IN PROOFof abnormalities in the leukocyte recruitment in DARC-
deficient mice would be more consistent with our hypoth- A new nomenclature for chemokine receptors has
esis [42]. As these mice did not display a phenotype been published, in which Duffy was separated from che-
under normal conditions, the main role of DARC seems mokine receptors with known signal transduction and is
to be during pathological responses. In addition to the referred to as a chemokine-binding protein.
erythroid-specific mutation leading to the “bone marrow Murphy PM, Baggiolini M, Charo IF, Hebert CA,
silent” in blacks, apparently healthy true Fy-null individ- Horuk R, Matsushima K, Miller LH, Oppenheim JJ,
uals have been described, which is consistent with this Power CA: International union of pharmacology. XXII.
view [43–45]. Nomenclature for chemokine receptors. Pharmacol Rev
An up-regulation of the CCR5 ligands RANTES, 52:145–176, 2000.
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